Your browser is no longer supported. Please, upgrade your browser.
Settings
BLUE bluebird bio, Inc. daily Stock Chart
BLUE [NASD]
bluebird bio, Inc.
Index- P/E- EPS (ttm)-10.67 Insider Own0.70% Shs Outstand54.74M Perf Week-10.99%
Market Cap7.50B Forward P/E- EPS next Y-10.50 Insider Trans-19.22% Shs Float54.60M Perf Month-10.76%
Income-555.60M PEG- EPS next Q-2.82 Inst Own- Short Float9.43% Perf Quarter8.35%
Sales54.60M P/S137.41 EPS this Y-5.30% Inst Trans0.05% Short Ratio10.18 Perf Half Y5.02%
Book/sh34.44 P/B3.98 EPS next Y10.30% ROA-27.00% Target Price177.61 Perf Year-21.57%
Cash/sh25.31 P/C5.42 EPS next 5Y- ROE-32.10% 52W Range87.49 - 199.70 Perf YTD38.17%
Dividend- P/FCF- EPS past 5Y-39.60% ROI-28.10% 52W High-31.37% Beta2.60
Dividend %- Quick Ratio9.70 Sales past 5Y22.00% Gross Margin- 52W Low56.66% ATR6.35
Employees764 Current Ratio9.70 Sales Q/Q357.10% Oper. Margin- RSI (14)36.87 Volatility5.38% 4.14%
OptionableYes Debt/Eq0.08 EPS Q/Q43.20% Profit Margin- Rel Volume1.60 Prev Close139.39
ShortableYes LT Debt/Eq0.08 EarningsFeb 20 Payout- Avg Volume505.80K Price137.06
Recom2.00 SMA20-11.23% SMA50-7.56% SMA200-1.50% Volume807,117 Change-1.67%
Mar-05-19Downgrade SVB Leerink Outperform → Mkt Perform
Feb-22-19Reiterated Cantor Fitzgerald Neutral $134 → $122
Dec-20-18Initiated Raymond James Strong Buy $165
Dec-06-18Downgrade Piper Jaffray Overweight → Neutral
Nov-14-18Upgrade Bernstein Mkt Perform → Outperform
Nov-05-18Upgrade Janney Neutral → Buy
Nov-02-18Upgrade Cantor Fitzgerald Underweight → Neutral $122 → $134
Jul-12-18Initiated Gabelli & Co Buy $239
Jun-19-18Upgrade Evercore ISI In-line → Outperform
Mar-21-18Reiterated Morgan Stanley Equal-Weight $152 → $209
Mar-14-18Initiated Janney Neutral
Mar-05-18Initiated William Blair Outperform
Feb-22-18Reiterated Cantor Fitzgerald Underweight $122 → $113
Jan-25-18Downgrade Leerink Partners Outperform → Mkt Perform
Dec-21-17Initiated Oppenheimer Perform
Dec-13-17Reiterated Barclays Overweight $162 → $209
Dec-13-17Downgrade Maxim Group Buy → Hold $200
Dec-11-17Upgrade Jefferies Hold → Buy $130 → $211
Dec-11-17Reiterated Goldman Buy $186 → $309
Dec-11-17Reiterated Cantor Fitzgerald Underweight $58 → $113
Apr-19-19 02:48PM  Top Gene-Sequencing Stocks for 2019 Motley Fool
Apr-18-19 02:45PM  Cambridge's bluebird bio expanding Kendall Square HQ American City Business Journals
Apr-17-19 05:15PM  Here's Why Shares of bluebird bio Slumped Today Motley Fool -9.50%
Apr-15-19 02:00PM  Four Companies Could Power The New Genomics ETF ETF Trends
Apr-09-19 10:52AM  Why bluebird bio Could Deliver Miracles to Genetic Disease Patients Motley Fool
09:53AM  5 Stocks in the Age of Miracles Motley Fool
Apr-08-19 06:11PM  Celgene & Acceleron Submit BLA for Luspatercept to the FDA Zacks
Apr-07-19 09:05AM  3 High-Growth Genomics Stocks You Can Buy Motley Fool
Mar-31-19 11:01AM  2 Blockbuster Gene Therapy Programs to Watch in 2019 Motley Fool
Mar-29-19 07:47AM  EMA panel recommends approval of Bluebird Bio's first gene therapy Reuters
07:44AM  bluebird bio Receives Positive Opinion from CHMP for ZYNTEGLO (autologous CD34+ cells encoding A-T87Q-globin gene) Gene Therapy for Patients 12 Years and Older with Transfusion-Dependent -Thalassemia (TDT) Who Do Not Have 0/0 Genotype Business Wire
07:36AM  EMA panel recommends approval of Bluebird Bio's first gene therapy Reuters
Mar-26-19 05:15PM  Celgene (CELG) Submits NDA for MS Drug to FDA for Review Zacks
Mar-25-19 08:24AM  Massachusetts concern details plan to hire new workers in Durham American City Business Journals
Mar-23-19 09:30AM  Why Is Bluebird (BLUE) Up 15.3% Since Last Earnings Report? Zacks
Mar-22-19 08:00AM  bluebird bio Opens State-of-the-Art Gene and Cell Therapy Manufacturing Facility in Durham, North Carolina Business Wire -6.11%
Mar-12-19 10:07AM  Celgene (CELG) Submits Application for MS Drug in Europe Zacks
Mar-11-19 02:28AM  Here's Why bluebird bio Gained 16.3% in February Motley Fool +5.89%
Mar-08-19 08:00AM  bluebird bio to Present at Investor Conferences in March Business Wire
Mar-07-19 12:32PM  What Are Analysts Saying About bluebird bio, Inc.s (NASDAQ:BLUE) Earnings Outlook? Simply Wall St.
Feb-26-19 04:21PM  With a Stocked War Chest, bluebird bio Presses On Motley Fool
11:15AM  Biotech ETFs Jump on Roche-Spark Deal Zacks
Feb-23-19 08:10PM  Better Buy: bluebird bio vs. Gilead Sciences Motley Fool
Feb-22-19 02:46PM  bluebird (BLUE) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
Feb-21-19 07:15PM  Bluebird Bio (BLUE) Reports Q4 Loss, Tops Revenue Estimates Zacks
06:17PM  Bluebird: 4Q Earnings Snapshot Associated Press
04:05PM  bluebird bio Reports Fourth Quarter and Full Year 2018 Financial Results and Highlights Operational Progress Business Wire
Feb-14-19 07:55AM  Report: Exploring Fundamental Drivers Behind Tyson Foods, ElectraMeccanica Vehicles, Cousins Properties, Spirit Aerosystems, bluebird bio, and Yext New Horizons, Emerging Trends, and Upcoming Developments GlobeNewswire
Feb-13-19 10:31AM  Earnings Preview: Bluebird Bio (BLUE) Q4 Earnings Expected to Decline Zacks
Feb-12-19 09:11AM  AbbVie Buys Rights to Novel Immunotherapy for Multiple Myeloma Zacks
Feb-11-19 06:30AM  bluebird bio Appoints Chip Baird as Chief Financial Officer Business Wire
Feb-06-19 01:52PM  Regeneron Q4 Earnings & Sales Beat on Strong Dupixent, Eylea Zacks
Feb-01-19 02:11PM  German firm that serves gene therapy biotechs opens Cambridge HQ American City Business Journals
Jan-31-19 11:46AM  Celgene (CELG) Q4 Earnings Beat Estimates, Revenues Up Y/Y Zacks
07:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Mirati Therapeutics ACCESSWIRE
Jan-28-19 11:52AM  Did bluebird bio, Inc. (NASDAQ:BLUE) Insiders Sell Shares? Simply Wall St.
Jan-24-19 10:51AM  The Zacks Analyst Blog Highlights: Celgene, Regeneron Pharmaceuticals, Amgen, Alnylam Pharmaceuticals and bluebird bio Zacks
10:12AM  Where Will bluebird bio Be in 5 Years? Motley Fool
Jan-23-19 10:48AM  5 Best Biotech Bets Likely to Outperform Estimates in Q4 Zacks
Jan-22-19 11:50AM  Here's Why CRISPR Therapeutics Stock Fell Today Motley Fool
Jan-21-19 02:00PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
Jan-12-19 09:41AM  Here's What Pushed bluebird bio Stock Down 44.3% in 2018 Motley Fool
07:31AM  3 Biotech Stocks to Watch in 2019 Motley Fool
Jan-11-19 09:56AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Investigation Against bluebird bio, Inc. (BLUE) ACCESSWIRE
06:55AM  Today's Research Reports on Trending Tickers: bluebird bio and Ultragenyx Pharmaceutical ACCESSWIRE
Jan-10-19 08:01AM  Three tech, three biotech companies that are top takeover targets in 2019 MarketWatch +6.03%
Jan-08-19 07:33PM  Biotech Proposes Paying for Pricey Drugs by Installment The Wall Street Journal
05:44PM  Biotech Proposes Paying for Pricey Drugs by Installment The Wall Street Journal
05:31PM  Celgene (CELG) Provides Guidance for 2019, Updates Pipeline Zacks
Jan-07-19 08:00AM  bluebird bio and Inhibrx Announce Collaboration to Research, Develop and Commercialize CAR T Cell Immunotherapies Business Wire +6.67%
Jan-04-19 12:16PM  Here's Why bluebird bio Shares Got Knocked Down 19.3% in December Motley Fool +6.66%
10:13AM  Bristol-Myers Becomes a Cancer-Fighting Giant With Celgene Buyout InvestorPlace
10:01AM  Bristol-Myers to Acquire Celgene: Healthcare ETFs in Focus Zacks
Jan-03-19 10:30AM  ONGOING INVESTIGATION NOTICE: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
08:00AM  bluebird bio to Present at the 37th Annual J.P. Morgan Healthcare Conference Business Wire
Dec-28-18 01:59PM  Lifshitz & Miller LLP Announces Investigation of Bluebird Bio, Inc., Cavco Industries, Inc., Edge Therapeutics, Inc., Inuvo, Inc., Lumentum Holdings, Inc., National Commerce Corporation, and Nobilis Health Corp. PR Newswire
Dec-27-18 01:00PM  ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm GlobeNewswire
12:30PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of bluebird bio, Inc. (BLUE) ACCESSWIRE
Dec-26-18 10:24AM  INVESTIGATION ALERT REMINDER: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire +8.39%
Dec-24-18 03:35PM  INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against bluebird bio, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm Business Wire
01:40PM  EQUITY ALERT: Rosen Law Firm Announces Investigation of Securities Claims Against bluebird bio, Inc. BLUE Business Wire
Dec-20-18 11:10AM  Bluebird Bio's Competitive Advantage Is Underappreciated, Raymond James Says In Bullish Initiation Benzinga -5.85%
Dec-19-18 08:23AM  Forget bluebird bio, Amgen Is a Better Biotech Stock Motley Fool
Dec-18-18 04:36PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE) Business Wire
Dec-17-18 12:46PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE) Business Wire
Dec-14-18 11:43AM  SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Certain Officers and Directors of bluebird bio, Inc. GlobeNewswire
Dec-13-18 02:14PM  Glancy Prongay & Murray LLP Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE) Business Wire -5.40%
Dec-12-18 06:42PM  INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Bluebird Bio, Inc. Investors (BLUE) Business Wire
08:11AM  bluebird bio, Inc. (NASDAQ:BLUE): Financial Strength Analysis Simply Wall St.
Dec-10-18 04:31PM  Why CRSP Stock Has Added Layers of Risk InvestorPlace
12:53PM  Is bluebird bio Inc (BLUE) A Good Stock To Buy? Insider Monkey
Dec-07-18 05:59PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of bluebird bio, Inc. BLUE GlobeNewswire -6.08%
Dec-06-18 08:56AM  Dow Drops 352 Points Because This Is Way More Than a Trade War Barrons.com
Dec-05-18 04:42PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of bluebird bio, Inc. - BLUE PR Newswire
11:25AM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of bluebird bio, Inc. (BLUE) GlobeNewswire
09:10AM  Biotech Stock Roundup: ASH Meet in Focus, Gilead's Drugs Get Approval in China Zacks
08:17AM  Can Celgene and bluebird bio Survive a Two-Pronged Attack? Motley Fool
Dec-04-18 08:13AM  Global Blood Therapeutics' Voxelotor on Faster Approval Path Zacks
06:50AM  Today's Research Reports on Trending Tickers: GlaxoSmithKline and bluebird bio ACCESSWIRE
12:20AM  Amgen antibody shows promise in myeloma trial, gets FDA fast track Reuters
Dec-03-18 09:15PM  bluebird bio Presents New Data for LentiGlobin Gene Therapy in Transfusion Dependent -Thalassemia at 60th Annual Meeting of the American Society of Hematology Business Wire -5.20%
09:15PM  bluebird bio Presents New Data for LentiGlobin Gene Therapy in Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology Business Wire
06:09PM  Celgene (CELG) Announces Various Cancer Data at ASH 2018 Zacks
Dec-02-18 07:30PM  bluebird bio and Celgene Corporation Present Initial Data from Ongoing Phase 1 Clinical Study of Next-Generation Anti-BCMA CAR T Cell Therapy bb21217 in Patients with Relapsed/Refractory Multiple Myeloma at ASH Annual Meeting Business Wire
Dec-01-18 05:00PM  bluebird bio Presents Updated Data from Clinical Studies of LentiGlobin Gene Therapy in Transfusion-Dependent -Thalassemia and Sickle Cell Disease at 60th Annual Meeting of the American Society of Hematology Business Wire
Nov-30-18 08:00AM  bluebird bio to Host Live Webcast of Investor and Analyst Event at the 60th Annual Meeting of the American Society of Hematology Business Wire
Nov-28-18 04:22PM  3 Themes To Watch As Biopharmas 'Bring Some Excitement' In Blood Cancer Investor's Business Daily
04:07PM  Celgene & Bluebird's CAR T Therapy Study Completes Enrollment Zacks
01:05PM  Leerink Starts Coverage Of Genetic Medicine Stocks: 'We See Commercial Execution As Increasingly Driving Returns' Benzinga
08:22AM  Biotech Stock Roundup: Pipeline Updates From CELG & VRTX, ZFGN Plunges on Hold News Zacks
Nov-19-18 04:13PM  3 High-Growth Stocks That Are Just Getting Started Motley Fool
Nov-18-18 09:51PM  Edited Transcript of BLUE earnings conference call or presentation 2-Nov-18 12:00pm GMT Thomson Reuters StreetEvents
Nov-17-18 08:31AM  My Top 3 Favorite Clinical-Stage Biotech Stocks to Buy Motley Fool
Nov-16-18 08:40AM  Market Trends Toward New Normal in PlayAGS, BEST, Inc. Sponsored ADR, Verrica Pharmaceuticals, Telenav, bluebird bio, and CompX International Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:00AM  Today's Research Reports on Trending Tickers: Intercept Pharmaceuticals and bluebird bio ACCESSWIRE
Nov-15-18 08:00AM  bluebird bio to Present at the Evercore ISI HealthCONx Conference Business Wire +5.40%
Nov-09-18 04:32PM  Waiting for bluebird bio to Sing at ASH Motley Fool
Nov-07-18 10:32PM  Here's Why bluebird bio Fell 21.4% in October Motley Fool
09:16AM  3 Cancer Stocks to Watch in December Motley Fool
08:24AM  3 Top Biotech Stocks to Buy in November Motley Fool
bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company's product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; and TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Walsh Jeffrey T.Chief Strategy OfficerApr 10Option Exercise24.471,50036,70542,421Apr 12 04:17 PM
Walsh Jeffrey T.Chief Strategy OfficerApr 10Sale156.651,500234,97640,921Apr 12 04:17 PM
Gregory Philip DChief Scientific OfficerApr 05Option Exercise64.021,30083,22633,892Apr 09 04:50 PM
Gregory Philip DChief Scientific OfficerApr 05Sale157.601,800283,68132,092Apr 09 04:50 PM
Davidson DavidChief Medical OfficerApr 04Option Exercise5.506,36034,98337,976Apr 08 04:11 PM
Davidson DavidChief Medical OfficerApr 04Sale160.066,3601,017,97631,616Apr 08 04:11 PM
Davidson DavidChief Medical OfficerMar 13Option Exercise5.503,10117,05734,717Mar 15 04:32 PM
Davidson DavidChief Medical OfficerMar 13Sale146.413,101454,00531,616Mar 15 04:32 PM
Walsh Jeffrey T.Chief Strategy OfficerMar 11Option Exercise24.471,50036,70542,421Mar 13 04:14 PM
Walsh Jeffrey T.Chief Strategy OfficerMar 11Sale139.801,500209,69840,921Mar 13 04:14 PM
Gregory Philip DChief Scientific OfficerMar 05Option Exercise64.021,30083,22634,392Mar 07 04:26 PM
Gregory Philip DChief Scientific OfficerMar 05Sale147.711,800265,87932,592Mar 07 04:26 PM
Davidson DavidChief Medical OfficerMar 04Option Exercise50.514,910248,00436,526Mar 06 04:32 PM
Davidson DavidChief Medical OfficerMar 04Sale155.774,910764,83231,616Mar 06 04:32 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerFeb 28Sale151.71517,7376,695Mar 04 04:34 PM
Cole JasonChief Operating andFeb 25Option Exercise40.446,248252,68732,692Feb 27 04:59 PM
Cole JasonChief Operating andFeb 25Sale150.246,248938,69826,444Feb 27 04:59 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerFeb 25Sale150.0020831,2016,746Feb 27 04:57 PM
Walsh Jeffrey T.Chief Financial andFeb 08Option Exercise24.471,50036,70542,421Feb 12 04:11 PM
Walsh Jeffrey T.Chief Financial andFeb 08Sale131.291,500196,92840,921Feb 12 04:11 PM
Gregory Philip DChief Scientific OfficerFeb 05Option Exercise64.021,30083,22634,892Feb 07 05:21 PM
Gregory Philip DChief Scientific OfficerFeb 05Sale137.991,800248,38333,092Feb 07 05:21 PM
Davidson DavidChief Medical OfficerFeb 04Option Exercise31.664,910155,43236,526Feb 05 05:58 PM
Davidson DavidChief Medical OfficerFeb 04Sale134.304,910659,41731,616Feb 05 05:58 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerJan 28Sale125.9620926,3264,403Jan 30 04:35 PM
Davidson DavidChief Medical OfficerJan 18Option Exercise24.472,03549,79624,276Jan 23 04:18 PM
Davidson DavidChief Medical OfficerJan 18Sale130.052,035264,64422,241Jan 23 04:18 PM
Gregory Philip DChief Scientific OfficerJan 16Option Exercise75.601,400105,84028,742Jan 18 04:03 PM
Walsh Jeffrey T.Chief FinancialJan 16Option Exercise24.473,00073,41035,483Jan 18 04:06 PM
Gregory Philip DChief Scientific OfficerJan 16Sale124.251,900236,06926,842Jan 18 04:03 PM
Walsh Jeffrey T.Chief FinancialJan 16Sale125.143,000375,42832,483Jan 18 04:06 PM
Gregory Philip DChief Scientific OfficerJan 07Option Exercise50.5160030,30631,221Jan 09 04:57 PM
FINGER ALISON CECILYChief Commercial OfficerJan 07Sale113.6464373,06814,548Jan 09 04:53 PM
Davidson DavidChief Medical OfficerJan 07Sale113.642,664302,73422,241Jan 09 04:46 PM
Cole JasonChief Legal OfficerJan 07Sale113.641,416160,91420,194Jan 09 04:39 PM
Walsh Jeffrey T.Chief FinancialJan 07Sale113.643,012342,27632,483Jan 09 05:05 PM
Leschly NickPresident and CEOJan 07Sale113.647,374837,966193,203Jan 09 05:03 PM
Gregory Philip DChief Scientific OfficerJan 07Sale112.493,879436,36327,342Jan 09 04:57 PM
Davidson DavidChief Medical OfficerJan 03Option Exercise24.471002,44725,005Jan 04 04:17 PM
FINGER ALISON CECILYChief Commercial OfficerJan 03Sale99.3142842,50615,239Jan 07 04:39 PM
Davidson DavidChief Medical OfficerJan 03Sale100.3210010,03224,905Jan 04 04:17 PM
Davidson DavidChief Medical OfficerJan 02Option Exercise17.397,500130,41029,605Jan 04 04:17 PM
Davidson DavidChief Medical OfficerJan 02Sale98.807,500741,02824,905Jan 04 04:17 PM
WENTWORTH KORY JAMESPrincipal Accounting OfficerDec 19Sale103.0538839,9834,612Dec 21 04:26 PM
Gregory Philip DChief Scientific OfficerDec 06Option Exercise50.5160030,30631,471Dec 10 04:09 PM
HIGH SUSANNA GATTIChief Operating OfficerDec 06Sale105.711,875198,19813,735Dec 10 04:11 PM
Gregory Philip DChief Scientific OfficerDec 06Sale106.5685090,57730,621Dec 10 04:09 PM
Davidson DavidChief Medical OfficerDec 04Option Exercise5.502,00011,00126,905Dec 06 04:12 PM
Davidson DavidChief Medical OfficerDec 04Sale121.052,000242,10824,905Dec 06 04:12 PM
Davidson DavidChief Medical OfficerDec 03Option Exercise5.506,00033,00230,905Dec 06 04:12 PM
Davidson DavidChief Medical OfficerDec 03Sale113.596,000681,53824,905Dec 06 04:12 PM
HIGH SUSANNA GATTIChief Operating OfficerDec 03Sale113.831,890215,13515,610Dec 06 04:14 PM
Walsh Jeffrey T.Chief FinancialNov 09Option Exercise24.471,50036,70536,995Nov 14 04:10 PM
Walsh Jeffrey T.Chief FinancialNov 09Sale130.591,500195,89135,495Nov 14 04:10 PM
Gregory Philip DChief Scientific OfficerNov 05Option Exercise64.021,30083,22632,671Nov 07 04:14 PM
Gregory Philip DChief Scientific OfficerNov 05Sale137.381,800247,27730,871Nov 07 04:14 PM
Davidson DavidChief Medical OfficerNov 02Option Exercise5.505,00027,50229,905Nov 06 04:15 PM
Davidson DavidChief Medical OfficerNov 02Sale133.645,000668,21624,905Nov 06 04:15 PM
Walsh Jeffrey T.Chief FinancialOct 10Option Exercise24.471,50036,70536,995Oct 12 04:53 PM
Walsh Jeffrey T.Chief FinancialOct 10Sale135.231,500202,83935,495Oct 12 04:53 PM
Gregory Philip DChief Scientific OfficerOct 05Option Exercise64.021,30083,22633,171Oct 10 04:17 PM
Gregory Philip DChief Scientific OfficerOct 05Sale140.561,800253,00031,371Oct 10 04:17 PM
Davidson DavidChief Medical OfficerOct 02Option Exercise5.505,00027,50229,905Oct 04 04:21 PM
Davidson DavidChief Medical OfficerOct 02Sale139.325,000696,58824,905Oct 04 04:21 PM
Walsh Jeffrey T.Chief FinancialSep 10Option Exercise24.471,50036,70536,995Sep 12 04:12 PM
Mandell JamesDirectorSep 10Sale150.771,000150,7711,000Sep 12 04:07 PM
Walsh Jeffrey T.Chief FinancialSep 10Sale150.161,500225,24335,495Sep 12 04:12 PM
Gregory Philip DChief Scientific OfficerSep 05Option Exercise64.021,30083,22633,671Sep 07 04:32 PM
Gregory Philip DChief Scientific OfficerSep 05Sale163.021,800293,44131,871Sep 07 04:32 PM
Davidson DavidChief Medical OfficerSep 04Option Exercise5.507,00038,50331,905Sep 06 04:12 PM
Davidson DavidChief Medical OfficerSep 04Sale166.647,0001,166,49324,905Sep 06 04:12 PM
Walsh Jeffrey T.Chief FinancialAug 30Option Exercise10.8820,000217,68955,495Sep 04 05:03 PM
Walsh Jeffrey T.Chief FinancialAug 30Sale175.4020,0003,507,94835,495Sep 04 05:03 PM
FINGER ALISON CECILYChief Commercial OfficerAug 20Sale158.0725940,94015,667Aug 22 06:32 AM
Walsh Jeffrey T.Chief FinancialAug 10Option Exercise5.501,5008,25136,995Aug 14 04:47 PM
Walsh Jeffrey T.Chief FinancialAug 10Sale156.931,500235,38935,495Aug 14 04:47 PM
Cole JasonChief Legal OfficerAug 08Option Exercise22.534,43899,98821,610Aug 10 06:48 AM
Gregory Philip DChief Scientific OfficerAug 06Option Exercise64.021,30083,22634,171Aug 08 04:06 PM
Gregory Philip DChief Scientific OfficerAug 06Sale156.611,800281,88932,371Aug 08 04:06 PM
Davidson DavidChief Medical OfficerAug 02Option Exercise5.507,00038,50331,905Aug 06 04:08 PM
Walsh Jeffrey T.Chief FinancialAug 02Option Exercise5.5021,500118,25956,995Aug 06 04:10 PM
Davidson DavidChief Medical OfficerAug 02Sale150.377,0001,052,58524,905Aug 06 04:08 PM
Walsh Jeffrey T.Chief FinancialAug 02Sale152.0221,5003,268,49335,495Aug 06 04:10 PM
Davidson DavidChief Medical OfficerJul 11Option Exercise5.503,00016,50127,905Jul 13 04:31 PM
Davidson DavidChief Medical OfficerJul 11Sale180.153,000540,44324,905Jul 13 04:31 PM
Cole JasonChief Legal OfficerJul 09Sale170.255,126872,71517,172Jul 11 04:10 PM
Davidson DavidChief Medical OfficerJul 02Option Exercise5.5010,00055,00434,905Jul 03 04:10 PM
Davidson DavidChief Medical OfficerJul 02Sale153.9610,0001,539,60424,905Jul 03 04:10 PM
Gregory Philip DChief Scientific OfficerJun 18Sale178.413,901695,97825,371Jun 20 04:29 PM
Vachon MarkDirectorJun 14Sale189.991,000189,9920Jun 18 04:43 PM
Davidson DavidChief Medical OfficerJun 04Option Exercise24.4713,000318,11037,905Jun 06 04:39 PM
HIGH SUSANNA GATTIChief Operating OfficerJun 04Option Exercise68.653,500240,27521,000Jun 06 04:36 PM
Vachon MarkDirectorJun 04Option Exercise42.076,000252,4207,000Jun 06 04:42 PM
Vachon MarkDirectorJun 04Sale188.226,0001,129,3011,000Jun 06 04:42 PM
Davidson DavidChief Medical OfficerJun 04Sale187.8413,0002,441,96524,905Jun 06 04:39 PM
HIGH SUSANNA GATTIChief Operating OfficerJun 04Sale199.113,500696,89217,500Jun 06 04:36 PM
Cole JasonChief Legal OfficerMay 04Sale170.893,750640,84922,298May 08 04:18 PM
Davidson DavidChief Medical OfficerMay 02Option Exercise24.4713,000318,11037,905May 04 04:39 PM
Davidson DavidChief Medical OfficerMay 02Sale177.5213,0002,307,69624,905May 04 04:39 PM